198 related articles for article (PubMed ID: 34096050)
21. Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment.
Joshi TP; Duvic M
J Am Acad Dermatol; 2023 Jun; 88(6):e305-e306. PubMed ID: 36858155
[No Abstract] [Full Text] [Related]
22. Ulceration of the palms and soles. An unusual feature of cutaneous T-cell lymphoma.
Sheehan-Dare RA; Goodfield MJ; Williamson DM; Cotterill JA
Acta Derm Venereol; 1990; 70(6):523-5. PubMed ID: 1981432
[TBL] [Abstract][Full Text] [Related]
23. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis, staging, and monitoring of cutaneous T-cell lymphoma.
Wood GS; Greenberg HL
Dermatol Ther; 2003; 16(4):269-75. PubMed ID: 14686968
[TBL] [Abstract][Full Text] [Related]
25. A primary care approach to cutaneous T-cell lymphoma.
Macey WH
Nurse Pract; 2000 Apr; 25(4):82, 85-8, 91-4 passim. PubMed ID: 10790799
[TBL] [Abstract][Full Text] [Related]
26. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
27. Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.
Novelli S; García-Muret P; Mozos A; Sierra J; Briones J
Leuk Lymphoma; 2016 May; 57(5):1060-6. PubMed ID: 27096891
[TBL] [Abstract][Full Text] [Related]
28. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
Wobser M; Goebeler M
Pathologe; 2020 Feb; 41(1):79-94. PubMed ID: 31932947
[TBL] [Abstract][Full Text] [Related]
29. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
Wobser M; Goebeler M
Hautarzt; 2019 Oct; 70(10):815-830. PubMed ID: 31511903
[TBL] [Abstract][Full Text] [Related]
30. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
[No Abstract] [Full Text] [Related]
31. Non-Hodgkin Lymphoma: Examining Mycosis Fungoides and Sézary Syndrome in the Context of Oncology Nursing.
Ow KV; Brant JM
Clin J Oncol Nurs; 2021 Oct; 25(5):555-562. PubMed ID: 34533520
[TBL] [Abstract][Full Text] [Related]
32. [Rare variants of cutaneous T-cell lymphomas].
Goerdt S; Trautmann C; Kütting B; Ramaker J; Schmuth M; Thiel E; Luger T; Stein H; Orfanos CE
Hautarzt; 1996 Feb; 47(2):96-105. PubMed ID: 8868452
[TBL] [Abstract][Full Text] [Related]
33. CADM1: A molecule worth investigating in mycosis fungoides and Sézary syndrome.
Zhang S; Wang T; Liu Y
J Am Acad Dermatol; 2020 Apr; 82(4):e141-e142. PubMed ID: 31857109
[No Abstract] [Full Text] [Related]
34. How we treat mycosis fungoides and Sézary syndrome.
Khan N; Noor SJ; Horwitz S
Clin Adv Hematol Oncol; 2021 Sep; 19(9):573-581. PubMed ID: 34495021
[No Abstract] [Full Text] [Related]
35. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
[TBL] [Abstract][Full Text] [Related]
36. Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma.
Blom A; Beylot-Barry M; D'Incan M; Laroche L
J Am Acad Dermatol; 2011 Aug; 65(2):404-410. PubMed ID: 21550694
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
Jfri A; Smith JS; Larocca C
J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
[No Abstract] [Full Text] [Related]
38. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
Gunter SJ; Kim EJ
J Invest Dermatol; 2024 Apr; 144(4):855-861.e1. PubMed ID: 37925066
[TBL] [Abstract][Full Text] [Related]
39. [Item no 164: malignant lymphoma: cutaneous lymphoma].
Ann Dermatol Venereol; 2005 Oct; 132(10 Suppl):7S153-7S155. PubMed ID: 16419538
[No Abstract] [Full Text] [Related]
40. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
